Modality
ADC
MOA
PCSK9i
Target
CD3
Pathway
DDR
CSUPancreatic CaUrothelial Ca
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
Jan 2020
→ Jan 2027
Phase 2Current
NCT08426876
656 pts·Pancreatic Ca
2022-03→TBD·Not yet recruiting
NCT05909679
290 pts·Pancreatic Ca
2020-01→2027-01·Completed
946 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-2110mo awayPh3 Readout· Pancreatic Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P2/3
Complet…
P2/3
Not yet…
Catalysts
Ph3 Readout
2027-01-21 · 10mo away
Pancreatic Ca
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08426876 | Phase 2/3 | Pancreatic Ca | Not yet recr... | 656 | UPCR |
| NCT05909679 | Phase 2/3 | Pancreatic Ca | Completed | 290 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα |